TY  - JOUR
N1  - restricted - published by Thompson
ID  - epprod3610
UR  - http://www.biomedcentral.com/1472-4472/7?issue=11
IS  - 11
A1  - Ding, C
Y1  - 2006///
N2  - Vertex Pharmaceuticals Inc, in collaboration with Kissei
Pharmaceutical Co Ltd, is developing VX-702, one of a series of second-generation, orally active p38 MAP kinase inhibitors, for the potential treatment of inflammation, rheumatoid arthritis and cardiovascular diseases. In June 2005, a phase II clinical trial of VX-702 was initiated in rheumatoid arthritis. In July 2006, Vertex was planning to file an IND in the second half of 2006.
JF  - Current Opinion in Investigational Drugs
VL  - 7
SN  - 1472-4472
TI  - Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome
SP  - 1020
AV  - public
EP  - 1025
ER  -